Detalhe da pesquisa
1.
Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
Oncologist
; 29(1): 15-24, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37616543
2.
Sorafenib in Dupuytren and Ledderhose Disease.
Oncologist
; 27(3): e294-e296, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274715
3.
Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.
Radiology
; 302(3): 595-602, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931855
4.
Sorafenib for Advanced and Refractory Desmoid Tumors.
N Engl J Med
; 379(25): 2417-2428, 2018 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30575484
5.
Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings.
J Urol
; 205(4): 1055-1062, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207133
6.
Spindle Cell Lipoma Revisited: Common and Unusual Magnetic Resonance Imaging Findings in 54 Patients With New Observations.
J Comput Assist Tomogr
; 45(4): 564-570, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34270478
7.
Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study.
Ann Surg
; 271(4): 748-755, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30418203
8.
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.
Oncologist
; 24(6): 857-863, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30126857
9.
Myxoinflammatory Fibroblastic Sarcoma: Clinical, Imaging, Management and Outcome in 29 Patients.
J Comput Assist Tomogr
; 41(1): 104-115, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27560024
10.
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Eur J Nucl Med Mol Imaging
; 41(11): 2093-105, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25143071
11.
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.
Eur Urol
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38782695
12.
Biopsy of suspicious bone lesions in patients with a single known malignancy: prevalence of a second malignancy.
AJR Am J Roentgenol
; 201(6): 1309-14, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24261372
13.
Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging.
Skeletal Radiol
; 42(6): 809-18, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23318907
14.
Musculoskeletal tumours and tumour-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part B: malignant mimics of benign tumours.
Int Orthop
; 37(5): 877-82, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23417556
15.
Musculoskeletal tumors and tumor-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part A: benign conditions that may mimic malignancy.
Int Orthop
; 37(5): 871-6, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23436133
16.
Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes.
Radiology
; 264(3): 779-88, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22829683
17.
MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.
Clin Genitourin Cancer
; 20(4): 319-325, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35618599
18.
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.
Clin Cancer Res
; 28(8): 1586-1594, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35110418
19.
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
J Clin Oncol
; 40(21): 2333-2341, 2022 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298296
20.
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
Invest New Drugs
; 29(5): 1004-12, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20461440